Lineage Cell Therapeutics, Inc. Stock

Equities

LCTX

US53566P1093

Biotechnology & Medical Research

Market Closed - Nyse 04:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
1.18 USD +1.72% Intraday chart for Lineage Cell Therapeutics, Inc. +12.38% +8.26%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 17.54M Sales 2025 * 14.63M Capitalization 219M
Net income 2024 * -21M Net income 2025 * -25M EV / Sales 2024 * 12.5 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 15 x
P/E ratio 2024 *
-10.4 x
P/E ratio 2025 *
-9.37 x
Employees 72
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.57%
More Fundamentals * Assessed data
Dynamic Chart
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $1.4M, vs. Street Est of $1.36M MT
Lineage Cell Therapeutics, Inc. Announces 24 Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit CI
Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors CI
Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting CI
Transcript : Lineage Cell Therapeutics, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q4 Revenue $8.9M, vs. Street Est of $2.8M MT
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury CI
Lineage Cell Therapeutics Launches $14 Million Registered Direct Offering MT
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury CI
Transcript : Lineage Cell Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Posts Q3 Revenue $1.2M, vs. Street Est of $2.6M MT
Lineage Cell Therapeutics, Inc. Announces to Present Rg6501 Phase 1/2A Results to Be Featured At Eyecelerator At 2023 American Academy of Ophthalmology CI
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration CI
More news

Latest transcript on Lineage Cell Therapeutics, Inc.

1 day+1.72%
1 week+12.38%
Current month+8.26%
1 month-15.71%
3 months+9.26%
6 months+10.28%
Current year+8.26%
More quotes
1 week
1.07
Extreme 1.07
1.40
1 month
1.04
Extreme 1.04
1.45
Current year
0.84
Extreme 0.8414
1.61
1 year
0.84
Extreme 0.8414
1.61
3 years
0.84
Extreme 0.8414
3.00
5 years
0.53
Extreme 0.5339
3.13
10 years
0.53
Extreme 0.5339
5.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 18-09-16
Director of Finance/CFO 48 22-11-13
Chief Operating Officer - 09-12-31
Members of the board TitleAgeSince
Director/Board Member 58 09-06-30
Chief Executive Officer 53 18-09-16
Director/Board Member 66 14-04-10
More insiders
Date Price Change Volume
24-05-09 1.18 +1.72% 716,352
24-05-08 1.16 -7.94% 915,518
24-05-07 1.26 -3.08% 1,221,577
24-05-06 1.3 +22.64% 4,103,213
24-05-03 1.06 +0.95% 614,788

Delayed Quote Nyse, May 09, 2024 at 04:00 pm EDT

More quotes
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.18 USD
Average target price
5.2 USD
Spread / Average Target
+340.68%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW